Shares of Inovio Pharmaceuticals Inc. (NASDAQ:INO) have earned a consensus rating of “Buy” from the eight research firms that are presently covering the firm. Two equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $17.85.

INO has been the topic of several research analyst reports. Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, September 14th. HC Wainwright assumed coverage on Inovio Pharmaceuticals in a research report on Monday, August 29th. They set a “buy” rating and a $17.00 price objective for the company. Brean Capital assumed coverage on Inovio Pharmaceuticals in a research report on Tuesday, October 4th. They set a “buy” rating and a $18.00 price objective for the company. Rodman & Renshaw restated a “buy” rating and set a $17.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, June 21st. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $31.00 price objective on shares of Inovio Pharmaceuticals in a research report on Monday, July 18th.

Inovio Pharmaceuticals (NASDAQ:INO) traded down 5.27% on Monday, hitting $8.09. The stock had a trading volume of 1,029,465 shares. The firm’s market cap is $595.00 million. Inovio Pharmaceuticals has a one year low of $4.50 and a one year high of $11.69. The company’s 50-day moving average price is $9.25 and its 200 day moving average price is $9.61.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The firm had revenue of $6.20 million for the quarter, compared to analysts’ expectations of $4.95 million. Inovio Pharmaceuticals had a negative return on equity of 22.29% and a negative net margin of 88.19%. Inovio Pharmaceuticals’s revenue was up 17.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.09) EPS. Analysts expect that Inovio Pharmaceuticals will post ($0.93) earnings per share for the current year.

In other Inovio Pharmaceuticals news, COO Niranjan Sardesai sold 21,800 shares of the business’s stock in a transaction on Monday, August 29th. The stock was sold at an average price of $9.30, for a total value of $202,740.00. Following the completion of the transaction, the chief operating officer now directly owns 70,234 shares in the company, valued at approximately $653,176.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.90% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in INO. ProShare Advisors LLC increased its stake in Inovio Pharmaceuticals by 0.5% in the second quarter. ProShare Advisors LLC now owns 62,527 shares of the biopharmaceutical company’s stock worth $578,000 after buying an additional 310 shares during the last quarter. Raymond James & Associates increased its stake in Inovio Pharmaceuticals by 9.8% in the second quarter. Raymond James & Associates now owns 11,313 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 1,013 shares during the last quarter. BlackRock Group LTD increased its stake in Inovio Pharmaceuticals by 4.6% in the second quarter. BlackRock Group LTD now owns 23,081 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 1,017 shares during the last quarter. Teachers Advisors Inc. increased its stake in Inovio Pharmaceuticals by 0.7% in the second quarter. Teachers Advisors Inc. now owns 148,647 shares of the biopharmaceutical company’s stock worth $1,373,000 after buying an additional 1,067 shares during the last quarter. Finally, Tocqueville Asset Management L.P. increased its stake in Inovio Pharmaceuticals by 1.7% in the second quarter. Tocqueville Asset Management L.P. now owns 71,600 shares of the biopharmaceutical company’s stock worth $662,000 after buying an additional 1,200 shares during the last quarter. Institutional investors and hedge funds own 28.59% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

5 Day Chart for NASDAQ:INO

Receive News & Stock Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.